Pfizer Inc. (PFE)

36.73 +0.03 (+0.08%) At close: 4:00PM EST

Pfizer Inc.

235 East 42nd Street
New York, NY 10017
United States
212 733 2323
http://www.pfizer.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 88,300

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Albert Bourla D.V.M., DVM, Ph.D.	Chairman & CEO	5.84M	2.12M	1962
Mr. John D. Young	Group Pres & Chief Bus. Officer	3.36M	3.83M	1965
Mr. Frank A. D'Amelio	CFO & Exec. VP of Global Supply	3.84M	8.47M	1958
Dr. Mikael Dolsten	Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical	3.66M	7.93M	1959
Ms. Jennifer B. Damico	Sr. VP, Controller & Principal Accounting Officer	N/A	N/A	1968
Ms. Lidia L. Fonseca	Exec. VP and Chief Digital & Technology Officer	N/A	N/A	1969
Mr. Charles E. Triano	Sr. VP of Investor Relations	N/A	N/A	N/A
Mr. Douglas M. Lankler	Exec. VP & Gen. Counsel	N/A	N/A	1966
Mr. Rady A. Johnson	Exec. VP and Chief Compliance, Quality & Risk Officer	N/A	N/A	1962
Dr. Alexander Rod MacKenzie	Chief Devel. Officer & Exec. VP of Global Product Devel.	N/A	N/A	1960

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company, Astellas Pharma US, Inc., and Myovant Sciences Ltd.; a licensing agreement with Akcea Therapeutics, Inc; a strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; a clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; collaboration agreement with BioNTech SE; a clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; a research collaboration and license agreement with BioInvent International AB; a drug discovery collaboration with Sosei Group Corporation; and collaboration with LianBio. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Corporate Governance

Pfizer Inc.’s ISS Governance QualityScore as of December 1, 2020 is 2. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.